We revolutionize
human health
through early
drug discovery


New antibiotics

for the war against antimicrobial resistance (AMR)

According to the World Health Organization (WHO) the antimicrobial resistance will cause 10 million deaths worldwide in 2050.

This issue is included in the list of “urgent global health problems” (WHO,2020)

In 2017, WHO published the first ever list of 12 families of bacteria that pose the greatest threat to human health and in 2022 published the first fungal priority pathogens list.

The discovery of new antibiotics represents a health emergency and a market opportunity.


An innovative natural source to discover new pharmaceutical products

Despite the extensive historical progress in the early discovery of anti-infective agents, the fungal kingdom remains an inexhaustible source of obtaining new chemical structures to address drug development.

Chances to find unidentified fungal species and novel bioactive fungal products are still high.

About us

Hifas Biologics is a biotechnology company focused on early drug discovery based on fungi as a natural source of pharmaceuticals. We leverage the accumulated knowledge of Hifas da Terra over more than 20 years of experience in research and validation of the functional properties of fungi. With this starting point, we employ molecular identification strategies with a clear focus on early-stage drug development for significant unmet medical needs.


proprietary strains of fungi


Clinical trials


years of experience

We are leading

The redefinition of the drug discovery process from fungi



Hifas Biologics comprises an exceptionally skilled and multidisciplinary team, encompassing individuals with diverse expertise and a collective drive to push the frontiers of science. Our common passion lies in enhancing human health by exploring the potential of fungi and uncovering novel drug discoveries.


The management team of Hifas Biologics is a remarkable combination of experienced and passionate leaders who are committed to the company's vision and values. Each member of the team brings extensive expertise in their respective field and a strong track record in the biotechnology and healthcare industry. Their deep knowledge and strategic leadership are instrumental in guiding the company towards success. 

Unmet medical needs

The unmet medical needs in the field of antibiotics are a crucial challenge in public health. Despite advances in medicine, antibiotic resistance has become a growing threat, limiting the effectiveness of conventional treatments. There is an urgent need to develop new antibiotics that are effective against resistant bacteria and address difficult-to-treat infections. These challenges require an innovative and collaborative approach that drives research and the discovery of new antibiotics, with the goal of improving healthcare and preserving the effectiveness of these vital medications. 

Be part of the company
Fleming would’ve invested in